Targeting PDGF signaling of cancer-associated fibroblasts blocks feedback activation of HIF-1α and tumor progression of clear cell ovarian cancer

Yutaro Mori,Yoshie Okimoto,Hiroaki Sakai,Yusuke Kanda,Hirokazu Ohata,Daisuke Shiokawa,Mikiko Suzuki,Hiroshi Yoshida,Haruka Ueda,Tomoyuki Sekizuka,Ryo Tamura,Kaoru Yamawaki,Tatsuya Ishiguro,Raul Nicolas Mateos,Yuichi Shiraishi,Yasushi Yatabe,Akinobu Hamada,Kosuke Yoshihara,Takayuki Enomoto,Koji Okamoto

DOI: https://doi.org/10.1016/j.xcrm.2024.101532

2024-05-21

Abstract:Ovarian clear cell carcinoma (OCCC) is a gynecological cancer with a dismal prognosis; however, the mechanism underlying OCCC chemoresistance is not well understood. To explore the intracellular networks associated with the chemoresistance, we analyze surgical specimens by performing integrative analyses that combine single-cell analyses and spatial transcriptomics. We find that a chemoresistant OCCC subpopulation with elevated HIF activity localizes mainly in areas populated by cancer-associated fibroblasts (CAFs) with a myofibroblastic phenotype, which is corroborated by quantitative immunostaining. CAF-enhanced chemoresistance and HIF-1α induction are recapitulated in co-culture assays, which show that cancer-derived platelet-derived growth factor (PDGF) contributes to the chemoresistance and HIF-1α induction via PDGF receptor signaling in CAFs. Ripretinib is identified as an effective receptor tyrosine kinase inhibitor against CAF survival. In the co-culture system and xenograft tumors, ripretinib prevents CAF survival and suppresses OCCC proliferation in the presence of carboplatin, indicating that combination of conventional chemotherapy and CAF-targeted agents is effective against OCCC.